4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $198,193 | -98.4% | 15,569 | -97.7% | 0.00% | -100.0% |
Q2 2023 | $12,218,084 | +785.5% | 676,153 | +742.4% | 0.01% | +500.0% |
Q1 2023 | $1,379,790 | -17.1% | 80,267 | +7.1% | 0.00% | 0.0% |
Q4 2022 | $1,665,061 | +182.7% | 74,969 | +2.2% | 0.00% | – |
Q3 2022 | $589,000 | +533.3% | 73,320 | +451.6% | 0.00% | – |
Q2 2022 | $93,000 | -60.4% | 13,293 | -14.3% | 0.00% | – |
Q1 2022 | $235,000 | -38.0% | 15,519 | -10.2% | 0.00% | – |
Q4 2021 | $379,000 | -16.5% | 17,283 | +2.5% | 0.00% | – |
Q3 2021 | $454,000 | +76.7% | 16,861 | +58.5% | 0.00% | – |
Q2 2021 | $257,000 | -39.1% | 10,641 | +9.6% | 0.00% | – |
Q1 2021 | $422,000 | – | 9,711 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |